

Docket No. 29888-5

PATENTCERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on Dec. 16, 2005

Holly D. KozlowskiIN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Mallen Huang : Paper No.:

Serial No.: 10/551,804 : Group Art Unit:

Filing Date: September 30, 2005 : Examiner:

For: **Nucleotide Vaccine Composition**

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56 and 1.97-1.98, Applicants cite the references listed on the attached Form PTO-1449. Copies of the non-U.S. patent references are enclosed.

Since the present statement is submitted prior to a first Official Action, no statement or fee under 37 C.F.R. §1.97 is required (37 C.F.R. §1.97(b)(1)).

Please charge any fee required in connection with this Statement to Deposit Account 04-1133.

Respectfully submitted,

Holly D. Kozlowski

Holly D. Kozlowski, Reg. No. 30,468
 Dinsmore & Shohl LLP
 1900 Chemed Center
 255 East Fifth Street
 Cincinnati, Ohio 45202
 (513) 977-8568

PTO FORM 4/92		Page 1 of 1											
FORM PTO - 1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT							ATTY DOCKET: 29888-5 APPLICANT: Mallen Huang FILING DATE: September 30, 2005 FOR: Nucleotide Vaccine Composition			SERIAL NO.: 10/551,804 GROUP:			
UNITED STATES LETTERS PATENT													
Exr. Init.		DOCUMENT NUMBER						DATE	NAME		CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY		CLASS	SUB CLASS	
aa	01	1	1	0	6	7		Feb. 15, 2001	PCT				
ab	00	5	4	8	3	9		Sept. 21, 2000	PCT				
ac	96	0	0	2	5	5		Feb. 1, 1996	PCT				
OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)													
ac	Ruobing Wang et al, "Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine", <i>Science</i> , Vol. 282, October, 1988, pp. 476-480.												
ad	John J. Donnelly et al, "DNA Vaccines", <i>Annu. Rev. Immunol.</i> , 1997, 15:617-48.												
ae	Sanjay Gurunathan et al, "DNA Vaccines: Immunology, Application, and Optimization", <i>Annu. Rev. Immunol.</i> , 2000, 18:927-974.												
af	John M. Timmerman et al, "Dendritic Cell Vaccines for Cancer Immunotherapy", <i>Annu. Rev. Med.</i> , 1999, 50:507-529.												
ag	Ching-Hsiang Hsu et al, "Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness <i>in vivo</i> by genetic immunization", <i>Nature Medicine</i> , Volume 2, Number 5, May 1996, pp. 540-544.												
ah	Ari Waisman et al, "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity", <i>Nature Medicine</i> , Volume 2, Number 8, August 1996, pp. 899-905.												
ai	Keiichi Kontani et al, "Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model", <i>Cancer Gene Therapy</i> , 2002, 9, 330, 337.												

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1215802v1